TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36726032

Group type: EXPERIMENTAL
Intervention: Palaeolithic diet (PD) adherence, characterized by high intake of fruit, vegetables, nuts, fish, and lean meat, and low intake of dairy, grains, legumes, refined sugar, and alcohol.
Number of subjects: 65574

Group type: EXPERIMENTAL
Intervention: Palaeolithic diet (PD) adherence (high adherence).
Number of subjects: 65574

Group type: COMPARATOR
Intervention: Palaeolithic diet (PD) adherence (low adherence).
Number of subjects: 65574
Study: 36726127

Group type: COMPARATOR
Intervention: Standard implementation of reSET and reSET-O digital therapeutics for substance use disorder (SUD) including clinician training and electronic health record tools.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Practice facilitation and/or health coaching as added implementation strategies.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard implementation of reSET and reSET-O digital therapeutics for SUD.
Number of subjects: 22
Study: 36726148

Group type: EXPERIMENTAL
Intervention: X chromosome variant near TMSB4X, rs5979771
Number of subjects: 10193

Group type: EXPERIMENTAL
Intervention: X chromosome genetic markers
Number of subjects: 10193

Group type: EXPERIMENTAL
Intervention: Sex differences in X chromosome variants
Number of subjects: 10193
Study: 36726187

Group type: EXPERIMENTAL
Intervention: Individualized, nurse-led follow-up with a focus on patient empowerment and use of electronic patient-reported outcome measures (ePROMs).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard, physician-led follow-up without use of ePROMs or specific focus on empowerment.
Number of subjects: 0
Study: 36726191

Group type: EXPERIMENTAL
Intervention: ACS-NSQIP
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Surgeon-adjusted ACS-NSQIP
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: NELA
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: P-POSSUM
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Predictive Optimal Trees in Emergency Surgery Risk
Number of subjects: 631
Study: 36726737

Group type: EXPERIMENTAL
Intervention: Benralizumab 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Benralizumab (all doses)
Number of subjects: 36
Study: 36726971

Group type: EXPERIMENTAL
Intervention: CD19-targeted CAR T cells (29 axi-cel, 24 tisa-cel)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pre-CAR-T systemic inflammation
Number of subjects: 53
Study: 36727004

Group type: EXPERIMENTAL
Intervention: STS + Kangaroo care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kangaroo care
Number of subjects: 0
Study: 36727105

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment for 1 year
Number of subjects: 35
Study: 36727222

Group type: EXPERIMENTAL
Intervention: Anlotinib in combination with CAPEOX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bevacizumab in combination with CAPEOX
Number of subjects: 0
Study: 36727397

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor therapy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Gene expression predictive models
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Top 20 pathways overexpressed in good responders
Number of subjects: 112
Study: 36727470

Group type: EXPERIMENTAL
Intervention: Sarilumab Monotherapy (n=111)
Number of subjects: 2541

Group type: EXPERIMENTAL
Intervention: Sarilumab + csDMARD (n=1910)
Number of subjects: 2541

Group type: EXPERIMENTAL
Intervention: Continuation (n=165)
Number of subjects: 2541

Group type: EXPERIMENTAL
Intervention: Switch (n=155)
Number of subjects: 2541

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 2541
Study: 36727741

Group type: EXPERIMENTAL
Intervention: Etoposide plus lobaplatin (EL) with concurrent thoracic radiotherapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP) with concurrent thoracic radiotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Etoposide plus lobaplatin (EL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both EL and EP
Number of subjects: 42
Study: 36727801

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy
Number of subjects: 57
Study: 36727855

Group type: EXPERIMENTAL
Intervention: NOL-guided fentanyl administration
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine care (fentanyl given per clinical routine)
Number of subjects: 72
Study: 36727866

Group type: EXPERIMENTAL
Intervention: 68 Ga-P16-093 PET/CT
Number of subjects: 30
Study: 36727868

Group type: EXPERIMENTAL
Intervention: Tulobuterol patch (1 mg)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 36728001

Group type: EXPERIMENTAL
Intervention: Liberal oxygenation target (Sp o2 > 94%)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conservative oxygenation target (Sp o2 88-92%)
Number of subjects: 75
Study: 36728126

Group type: EXPERIMENTAL
Intervention: AI software tool for CI programming
Number of subjects: 47
Study: 36728139

Group type: EXPERIMENTAL
Intervention: 68 Ga-PSMA PET/CT
Number of subjects: 1

Group type: COMPARATOR
Intervention: 18 F-fluciclovine PET/CT
Number of subjects: 1
Study: 36728194

Group type: EXPERIMENTAL
Intervention: Social support at 3 months
Number of subjects: 161

Group type: COMPARATOR
Intervention: Any therapy
Number of subjects: 161
Study: 36728214

Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF) for 4 years
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: TDF withdrawal
Number of subjects: 201
Study: 36728217

Group type: EXPERIMENTAL
Intervention: Preemptive antiviral therapy with tenofovir disoproxil fumarate (TDF)
Number of subjects: 73
Study: 36728233

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-surgical intervention
Number of subjects: 0
Study: 36728302

Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP) using the OrganOx metra device for a minimum of 4 hours.
Number of subjects: 22
Study: 36728303

Group type: EXPERIMENTAL
Intervention: Low-dose ICG (0.05 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard-dose ICG (2.5 mg)
Number of subjects: 55
Study: 36728375

Group type: EXPERIMENTAL
Intervention: ciNPT (Prevena Incision Management System, 3M Health Care)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional wound care
Number of subjects: 144
Study: 36728532

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) at <12 h
Number of subjects: 59447

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) at 12 to 24 h
Number of subjects: 59447

Group type: EXPERIMENTAL
Intervention: Pharmaco-invasive strategy
Number of subjects: 59447

Group type: COMPARATOR
Intervention: Fibrinolysis alone
Number of subjects: 59447
Study: 36728573

Group type: EXPERIMENTAL
Intervention: Two-sample strategy (T0 + T6)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Two-sample strategy (T0 + T1)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: One-sample strategy (T6 only)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Three-sample strategy (T0, T1, T6)
Number of subjects: 77
Study: 36728649

Group type: EXPERIMENTAL
Intervention: Rusfertide (hepcidin mimetic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36728653

Group type: EXPERIMENTAL
Intervention: Varenicline solution nasal spray (VNS) 0.03 mg
Number of subjects: 602
Study: 36728848

Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 36728874

Group type: EXPERIMENTAL
Intervention: Biweekly intravitreal aflibercept injections (IAI) 2 mg
Number of subjects: 22
Study: 36728954

Group type: EXPERIMENTAL
Intervention: Targeted, nurse-directed sedation strategy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 102
Study: 36728974

Group type: EXPERIMENTAL
Intervention: Total daily physical activity (PA)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Meeting physical activity recommendations
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: K-means clustering based on percent of time spent in MVPA and ST
Number of subjects: 124
Study: 36729084

Group type: EXPERIMENTAL
Intervention: As-needed (PRN) ranibizumab therapy
Number of subjects: 222
Study: 36729239

Group type: EXPERIMENTAL
Intervention: Current caregivers
Number of subjects: 46

Group type: COMPARATOR
Intervention: Former caregivers
Number of subjects: 46
Study: 36729308

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 36729404

Group type: EXPERIMENTAL
Intervention: Gadopiclenol at 0.05 mmol/kg
Number of subjects: 256

Group type: COMPARATOR
Intervention: Gadobutrol at 0.1 mmol/kg
Number of subjects: 256
Study: 36729422

Group type: EXPERIMENTAL
Intervention: SB2 therapy for naïve CD patients
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: SB2 therapy for switched CD patients
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: SB2 therapy for all groups
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: SB2 therapy for naïve UC patients
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: SB2 therapy for switched UC patients
Number of subjects: 126
Study: 36729441

Group type: EXPERIMENTAL
Intervention: LipiFlow treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Warm compresses and eyelid massages
Number of subjects: 46
Study: 36729473

Group type: EXPERIMENTAL
Intervention: Oral, topical, and/or adjuvant agents for neuropathic mechanisms
Number of subjects: 0
Study: 36729494

Group type: EXPERIMENTAL
Intervention: Network-informed personalized treatment
Number of subjects: 79
Study: 36729506

Group type: EXPERIMENTAL
Intervention: High-resolution microendoscopy (HRME) with a multitask deep learning network (MTN) for automated diagnosis of AIN 2+
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High-resolution microendoscopy (HRME)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High-resolution microendoscopy (HRME) combined with HRA
Number of subjects: 77
Study: 36729514

Group type: EXPERIMENTAL
Intervention: PEEP 15 cm H2O
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PEEP 10 cm H2O
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PEEP 5 cm H2O
Number of subjects: 23
Study: 36729538

Group type: EXPERIMENTAL
Intervention: Revised HIV Care Coordination Program (CCP)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Original HIV Care Coordination Program (CCP)
Number of subjects: 960
Study: 36729552

Group type: EXPERIMENTAL
Intervention: COMPASS intervention (early supported discharge)
Number of subjects: 2262

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2262

Group type: EXPERIMENTAL
Intervention: COMPASS intervention
Number of subjects: 2262
Study: 36729587

Group type: EXPERIMENTAL
Intervention: Median nerve stimulation during general anesthesia with propofol.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Median nerve stimulation with varying propofol concentrations.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Application of 4 different offline machine learning algorithms.
Number of subjects: 30
Study: 36729610

Group type: EXPERIMENTAL
Intervention: Outer retinal tubulation (ORT) present
Number of subjects: 42
Study: 36729711

Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention (one-off)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention (annual)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control scenario (no crowdsourcing)
Number of subjects: 0
Study: 36729811

Group type: EXPERIMENTAL
Intervention: 3D TSE T1-WI
Number of subjects: 158

Group type: COMPARATOR
Intervention: 3D GRE T1-WI
Number of subjects: 158
Study: 36729896

Group type: EXPERIMENTAL
Intervention: SIGN@L-A (serious game with playful elements)
Number of subjects: 28

Group type: COMPARATOR
Intervention: SIGN@L-B (serious game with only objectives and feedback)
Number of subjects: 28
Study: 36729923

Group type: EXPERIMENTAL
Intervention: Walking for 60 min at 60% of peak oxygen uptake
Number of subjects: 54

Group type: COMPARATOR
Intervention: Resting (Control)
Number of subjects: 54
Study: 36729947

Group type: EXPERIMENTAL
Intervention: Burnout measured using the Maslach Burnout Inventory-Human Service Survey
Number of subjects: 6331

Group type: EXPERIMENTAL
Intervention: COVID-19 exposure parameters, specifically redeployment outside normal professional boundaries
Number of subjects: 6331

Group type: EXPERIMENTAL
Intervention: Higher perceived institutional support
Number of subjects: 6331

Group type: EXPERIMENTAL
Intervention: Higher resilience
Number of subjects: 6331
Study: 36730056

Group type: EXPERIMENTAL
Intervention: Tilavonemab 300 mg
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Tilavonemab 1000 mg
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Tilavonemab 2000 mg
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study: 36730070

Group type: EXPERIMENTAL
Intervention: Glutamine administration
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 64
Study: 36730114

Group type: EXPERIMENTAL
Intervention: EUS-BD
Number of subjects: 145

Group type: COMPARATOR
Intervention: ERCP
Number of subjects: 145
Study: 36730145

Group type: EXPERIMENTAL
Intervention: Standard dose TPF (Docetaxel 75 mg/m2, Platinum 75 mg/m2, 5-Fluorouracil 750 mg/m2 IVCI x 5 days) followed by weekly cisplatin (40 mg/m2) or carboplatin (AUC 1.5) concurrent with radiation therapy of 70 Gy over 6.5-7 weeks.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Standard dose TPF followed by concurrent chemoradiation.
Number of subjects: 26
Study: 36730189

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Reoxygenation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 2
Study: 36730240

Group type: EXPERIMENTAL
Intervention: 20mg/kg/day rifampin for 60 days
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: 30mg/kg/day rifampin for 60 days
Number of subjects: 1359

Group type: COMPARATOR
Intervention: 10mg/kg/day rifampin for 120 days (control)
Number of subjects: 1359
Study: 36730289

Group type: EXPERIMENTAL
Intervention: Morning dosing of AZA or 6-MP
Number of subjects: 26

Group type: COMPARATOR
Intervention: Evening dosing of AZA or 6-MP
Number of subjects: 26
Study: 36730371

Group type: EXPERIMENTAL
Intervention: Video-graded intraoperative factors
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Unfavorable graft configuration (wrinkled, tight scroll, taco-shaped)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Gas-bubble size smaller than graft diameter
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Larger gas-bubble size
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Corrected distance visual acuity
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Endothelial cell density
Number of subjects: 65
Study: 36730749

Group type: EXPERIMENTAL
Intervention: Amphetamine Extended-Release Oral Suspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36730762

Group type: EXPERIMENTAL
Intervention: Triggered escalating real-time adherence intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 85
Study: 36730769

Group type: EXPERIMENTAL
Intervention: THC cutoff levels in blood and saliva
Number of subjects: 0
Study: 36730797

Group type: EXPERIMENTAL
Intervention: Dynamic incentivization (loss-based and streak)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flat-rate incentivization (monetary and electronic device)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EMA data
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clinical visits
Number of subjects: 30
Study: 36730884

Group type: EXPERIMENTAL
Intervention: ONCOTHROMB score
Number of subjects: 627

Group type: COMPARATOR
Intervention: Khorana score
Number of subjects: 627
Study: 36730946

Group type: EXPERIMENTAL
Intervention: Wavefront-guided PRK with the STAR S4 IR Excimer Laser System
Number of subjects: 167
Study: 36731003

Group type: EXPERIMENTAL
Intervention: Apixaban (2.5-5 mg BID)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Rivaroxaban (20 mg QD)
Number of subjects: 74
Study: 36731068

Group type: EXPERIMENTAL
Intervention: LVAD implantation
Number of subjects: 300
Study: 36731072

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Multidetector computed tomography (MDCT)
Number of subjects: 16
Study: 36731199

Group type: EXPERIMENTAL
Intervention: Yoga Nidra
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no Yoga Nidra)
Number of subjects: 22
Study: 36731493

Group type: EXPERIMENTAL
Intervention: Person-Centered Information for Parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36731578

Group type: EXPERIMENTAL
Intervention: Same-day discharge (SDD) after ESD
Number of subjects: 831

Group type: COMPARATOR
Intervention: Admission after ESD
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Factors associated with admission
Number of subjects: 831
Study: 36731585

Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg
Number of subjects: 221
Study: 36731588

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) treatment
Number of subjects: 117
Study: 36731604

Group type: EXPERIMENTAL
Intervention: Cardiovascular imaging
Number of subjects: 0
Study: 36731865

Group type: EXPERIMENTAL
Intervention: Early angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy initiated within 24 hours of admission.
Number of subjects: 7204
Study: 36732038

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 1358
Study: 36732049

Group type: EXPERIMENTAL
Intervention: Efmarodocokin alfa (30-90 µg/kg doses given once every 2 weeks or monthly for 12 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 36732164

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S 5 × 10^10 viral particles
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 36732571

Group type: EXPERIMENTAL
Intervention: Premeal almond load (20 g) before OGTT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Premeal almond load (20 g) before three major meals
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 60
Study: 36732627

Group type: EXPERIMENTAL
Intervention: Serplulimab (3 mg/kg) plus cisplatin (50 mg/m2)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo plus cisplatin (50 mg/m2)
Number of subjects: 551
Study: 36732628

Group type: EXPERIMENTAL
Intervention: ipilimumab 3 mg/kg plus nivolumab
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Presurgical absence of circulating tumor DNA (ctDNA) in urine and plasma
Number of subjects: 30
Study: 36732694

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs) completed at the start and every 6 months for 1 year, with healthcare provider prompted to view scores.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient-reported outcome measures (PROMs) completed at the start and again after 12 months, with neurologist not able to view scores.
Number of subjects: 0
Study: 36732734

Group type: EXPERIMENTAL
Intervention: Home monitoring program (I-FILE) including home spirometry, pulse oximetry, and patient-reported outcomes (PROMs) for two years.
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Daily home spirometry and pulse oximetry in the first three months, followed by once weekly measurements for two years.
Number of subjects: 700
Study: 36732788

Group type: EXPERIMENTAL
Intervention: Smartphone-based physical activity intervention (12 weeks)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 146
Study: 36732823

Group type: EXPERIMENTAL
Intervention: Online Pilates Group (OPG)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Face-to-Face Pilates Group (FPG)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 58
Study: 36732830

Group type: EXPERIMENTAL
Intervention: Reloading of P2Y12 receptor inhibitors
Number of subjects: 4790
Study: 36732920

Group type: EXPERIMENTAL
Intervention: Irisin levels in diabetic patients with CAD
Number of subjects: 100

Group type: COMPARATOR
Intervention: Irisin levels in diabetic patients without CAD
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Irisin levels as a predictor
Number of subjects: 100
Study: 36733279

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness levels during COVID-19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body mass index during COVID-19
Number of subjects: 0
Study: 36733374

Group type: EXPERIMENTAL
Intervention: SDI-118, a novel procognitive SV2A modulator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36733413

Group type: EXPERIMENTAL
Intervention: Pre-operative intravenous injection of butorphanol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 100
Study: 36733470

Group type: EXPERIMENTAL
Intervention: Personalized dietary advice (PDA) program delivered by a dietitian at baseline, 1 month, and 3 months.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard advice form (SAF)
Number of subjects: 182
Study: 36733480

Group type: EXPERIMENTAL
Intervention: Polyvalent mechanical bacterial lysate (PMBL) therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 36733485

Group type: COMPARATOR
Intervention: Toripalimab plus lenvatinib without radiotherapy (NRT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Toripalimab plus lenvatinib with radiotherapy (RT)
Number of subjects: 88
Study: 36734040

Group type: EXPERIMENTAL
Intervention: COBMINDEX
Number of subjects: 142

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 142